Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
Study Identifier:
ALXN1720-HV-101
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1720 SC
- Drug: ALXN1720 IV
- Drug: rHuPH20
- Drug: Placebo SC
- Drug: Placebo IV
Date
Sep 2019 - Nov 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years
Requirements Information
Sex
Female & Male
Age
18 - 45 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1720 SC
- Drug: ALXN1720 IV
- Drug: rHuPH20
- Drug: Placebo SC
- Drug: Placebo IV
Date
Sep 2019 - Nov 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years years
Requirements Information
Protocol Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALXN1720 administered subcutaneously (SC) or intravenously (IV).
Trial Locations
Location
Status
Location
Clinical Study Site
London, United Kingdom
Status
N/A